Literature DB >> 11592595

Venesection therapy of insulin resistance-associated hepatic iron overload.

A Guillygomarc'h1, M H Mendler, R Moirand, F Lainé, V Quentin, V David, P Brissot, Y Deugnier.   

Abstract

BACKGROUND/AIMS: The association of hepatic iron overload with metabolic disorders has been coined as the insulin resistance-associated hepatic iron overload syndrome (IR-HIO).
METHODS: Fifty-six IR-HIO patients were phlebotomized either weekly (n = 14) or bimonthly (n = 42) and compared with C282Y homozygotes and with ten IR-HIO patients treated by a low calorie diet alone.
RESULTS: In venesected patients, the median amount of mobilized iron was 0.6 g in 2.8 months in females and 1.8 g in 5 months in males. Mobilized iron did not differ depending on the frequency of venesections or HFE genotype. When compared with C282Y homozygotes, IR-HIO patients had a similar amount of mobilized iron, but three-fold serum ferritin levels. The presenting symptoms (chronic fatigue and/or polyarthralgias) improved in 6/7 patients. Phlebotomies were well tolerated. In patients treated by a low calorie diet, serum ferritin levels remained stable.
CONCLUSIONS: In IR-HIO patients, body iron stores are significantly increased, overestimated by serum ferritin, not modified by a low calorie diet, and safely removed by phlebotomies. Based on these data and on studies indicating that iron excess is associated with increased risk for hepatic fibrosis, cancer and cardiovascular disorders, venesection therapy can be recommended in IR-HIO patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592595     DOI: 10.1016/s0168-8278(01)00147-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

Review 1.  Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver.

Authors:  Elmar Aigner; Günter Weiss; Christian Datz
Journal:  World J Hepatol       Date:  2015-02-27

2.  A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Paola Dongiovanni; Serena Rovida; Raffaela Rametta; Erika Fatta; Edoardo Alessandro Pulixi; Marco Maggioni; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Gender-related variations in iron metabolism and liver diseases.

Authors:  Duygu D Harrison-Findik
Journal:  World J Hepatol       Date:  2010-08-27

4.  Factors influencing the rate of fibrosis progression in chronic hepatitis C.

Authors:  Conrado M Fernández-Rodriguez; Maria Luisa Gutiérrez; Pilar López Serrano; José L Lledó; Cecilio Santander; Teresa Pérez Fernández; Esperanza Tomás; Guillermo Cacho; Manuel Nevado; Maria Luisa Casas
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 5.  Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis.

Authors:  Shivakumar Chitturi; Jacob George
Journal:  Curr Gastroenterol Rep       Date:  2003-02

6.  Association between iron overload and osteoporosis in patients with hereditary hemochromatosis.

Authors:  L Valenti; M Varenna; A L Fracanzani; V Rossi; S Fargion; L Sinigaglia
Journal:  Osteoporos Int       Date:  2008-07-26       Impact factor: 4.507

Review 7.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

8.  The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.

Authors:  Leo R Zacharski; Ralph G DePalma; Galina Shamayeva; Bruce K Chow
Journal:  Am J Public Health       Date:  2013-02-14       Impact factor: 9.308

9.  Biomarkers of body iron stores and risk of developing type 2 diabetes.

Authors:  S N Rajpathak; J Wylie-Rosett; M J Gunter; A Negassa; G C Kabat; T E Rohan; J Crandall
Journal:  Diabetes Obes Metab       Date:  2009-01-21       Impact factor: 6.577

10.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Mary E Rinella
Journal:  Curr Hepatol Rep       Date:  2016-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.